Monopar Therapeutics Inc MNPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
Trading Information
- Previous Close Price
- $71.73
- Day Range
- $67.12–75.03
- 52-Week Range
- $50.07–124.82
- Bid/Ask
- $65.52 / $72.73
- Shares Outstanding
- 6.71M
- Market Cap
- $487.84M
- Volume/Avg
- 313,027 / 158,891
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 22
- Website
- https://www.monopartx.com
Valuation
Metric | MNPR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.68 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | MNPR |
|---|---|
Quick Ratio | 33.44 |
Current Ratio | 33.56 |
Interest Coverage | — |
Quick Ratio
MNPR
Profitability
Metric | MNPR |
|---|---|
Return on Assets (Normalized) | −10.23% |
Return on Equity (Normalized) | −10.47% |
Return on Invested Capital (Normalized) | −14.01% |
Return on Assets
MNPR
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%%V>N# | LOCK|tL$H | $139B | |||
| Moderna Inc MRNA | LOCK|#%@QNMm | LOCK|&% | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|VBH>H% | LOCK|hT$#k | $99B | |||
| argenx SE ADR ARGX | LOCK|L%!$xn | LOCK|&< | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$TSD^@@ | LOCK|?#y | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|ctQ<>$d | LOCK|bS%& | $31B | |||
| Incyte Corp INCY | LOCK|%B<x&r | LOCK|^T% | $25B | |||
| BioNTech SE ADR BNTX | LOCK|$l%pH#q | LOCK|%X | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|MFzY&^ | LOCK|@K<Y@ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|%>KXVK^ | LOCK|?Xm | $16B |
United States